percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. Withhold Vectibix for dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to ¿ grade 2 within 1 month, permanently discontinue Vectibix. The clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage were reported.
Infusion Reactions: Severe infusion reactions occurred in approximately 1 percent of patients. Severe infusion reactions included anaphylactic reactions, bronchospasm, and hypotension. Although not reported with Vectibix, fatal infusion reactions have occurred with other monoclonal antibody products. Stop infusion if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Forward-LookPage: 1 2 3 4 5 6 7 8 Related biology technology :1
. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network2
. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit3
. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)4
. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology5
. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China6
. PRA International to Present Audioconference on Oncology Research - Nov. 87
. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers8
. AG Mednet to Provide Image Network for Southwest Oncology Group9
. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology10
. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study11
. Oncology Metrics and Cureline Announce Joint Marketing Agreement